Fulgent Genetics, Inc.
NASDAQ:FLGTMedical - Diagnostics & Research
+$0.33 today
- Market cap
- $702.11M
- Beta
- 0.92
- P/E (TTM)
- -7.5
- EPS (TTM)
- -$2.39
Volume 0.39M
Average 0.55M
FLGT EPS (Diluted)
Earnings per share assuming conversion of dilutive securities such as options and convertible instruments.
Fulgent Genetics, Inc.NASDAQ: FLGT
EPS (Diluted) · Q1 FY2026 · quarter ended Mar 2026
EPS (Diluted) remains negative
Q1 FY2026 EPS (Diluted) was -$0.8, compared with -$0.37 a year earlier. Trailing-twelve-month EPS (Diluted) was -$2.38.
Context
- EPS (Diluted) increased in 1 of the last 3 fiscal years.
What to watch
Whether EPS (Diluted) reaches the consensus estimate from 1 analysts of -$1.7 (+13.7%) for the fiscal year ending Dec 2026, a step up from the -39.7% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$0.8-5.3% QoQ
- Last fiscal yearDec 2025
- -$1.97-39.7% YoY
- LTMMar 2026
- -$2.38-78.9% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -116.2% | +24.6% | +140.8 pp |
| 1 year | -39.7% | +13.7% | +53.4 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EPS (Diluted) history
USD · from the income statement
- Latest · FY2025
- (1.97) USD
- Year-over-year change
- -39.7%
| Period | Period end | EPS (Diluted) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (1.97) | -39.7% |
| FY2024 | 2024-12-31 | (1.41) | +75.0% |
| FY2023 | 2023-12-31 | (5.63) | -221.6% |
| FY2022 | 2022-12-31 | 4.63 | -71.5% |
| FY2021 | 2021-12-31 | 16.26 | — |
EPS (Diluted) vs competitors
How FLGT compares with its peers on the latest reported figures
- FLGT's LTM Mar 2026 EPS (Diluted) of -$2.38 is the 5th highest of the 8 companies compared; the peer median is -$1.36.
- Its year-over-year change of -78.9% is the 6th highest of 8, against a peer median of +20.9%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
BLLNBillionToOne, Inc. | LTM Jun 2026 | $0.62 | +190.6% | — |
| LTM Jun 2026 | -$0.4 | +51.0% | — | |
| LTM Mar 2026 | -$1.02 | +20.9% | — | |
| LTM Jun 2026 | -$1.36 | +28.8% | — | |
| LTM Mar 2026 | -$2.38 | -78.9% | — | |
WGSGeneDx Holdings Corp. | LTM Jun 2026 | -$3.62 | -18200.0% | — |
| LTM Sep 2026 | -$3.68 | -14.6% | — | |
| LTM Mar 2026 | -$4.3 | -284.0% | — | |
FRNMFreenome, Inc. Common stock | — | — | — | — |
| Peer median (excluding FLGT) | -$1.36 | +20.9% | — | |
Competitors are the stored peer set for FLGT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 992.58M | 618.97M | 289.21M | 283.47M | 322.67M |
| Cost of Revenue | 215.53M | 252.07M | 184.76M | 176.26M | 191.8M |
| Gross Profit | 777.05M | 366.9M | 104.46M | 107.22M | 130.88M |
| Gross Margin | 78.3% | 59.3% | 36.1% | 37.8% | 40.6% |
| Research & Development | 24.22M | 28.91M | 41.44M | 48.82M | 53.91M |
| Selling, General & Admin | 75.17M | 149.99M | 130.47M | 124.35M | 160.04M |
| Operating Expenses | 101.1M | 188.37M | 299.99M | 181.13M | 221.97M |
| Depreciation & Amortization | 11M | 32.66M | 26.14M | 24.93M | 24.12M |
| EBITDA | 692.04M | 217.7M | (147.45M) | (26.86M) | (45.83M) |
| EBITDA Margin | 69.7% | 35.2% | -51.0% | -9.5% | -14.2% |
| Operating Income | 675.95M | 178.53M | (195.53M) | (73.92M) | (91.1M) |
| Operating Margin | 68.1% | 28.8% | -67.6% | -26.1% | -28.2% |
| Interest Income | 1.35M | 5.62M | 21.61M | 31.3M | 30.92M |
| Interest Expense | 0 | 1.01M | 488K | 170K | 75K |
| Other Income / Expenses | 5.08M | 5.5M | 21.44M | 21.96M | 21.07M |
| Income Before Tax | 681.03M | 184.03M | (174.09M) | (51.96M) | (70.03M) |
| Pre-Tax Margin | 68.6% | 29.7% | -60.2% | -18.3% | -21.7% |
| Income Tax Expense | 174.8M | 42.1M | 1.15M | (8.14M) | (8.39M) |
| Net Income | 507.36M | 143.4M | (167.83M) | (42.71M) | (60.51M) |
| Net Margin | 51.1% | 23.2% | -58.0% | -15.1% | -18.8% |
| EPS (Basic) | 17.13 | 4.76 | (5.63) | (1.41) | (1.97) |
| EPS (Diluted) | 16.26 | 4.63 | (5.63) | (1.41) | (1.97) |
| Weighted Avg Shares | 29.41M | 30.1M | 29.78M | 30.24M | 30.78M |
| Weighted Avg Shares (Diluted) | 30.98M | 30.96M | 29.78M | 30.24M | 30.78M |
Fulgent Genetics, Inc.
NASDAQ:FLGT
Intrinsic Alpha fair value
Locked
Current Price
$25.13
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.